Vitamin D in chronic kidney disease: Is there a role outside of PTH control?

Research output: Contribution to journalReview article

Abstract

Purpose of reviewVitamin D deficiency is common in patients with kidney disease and many patients receive vitamin D supplementation. Several large, well-designed clinical trials have been published in the last few years evaluating the effects of vitamin D supplementation on important outcomes for patients with kidney disease including effects on cardiovascular disease, secondary hyperparathyroidism, and kidney disease progression.Recent findingsSeveral negative trials have been published showing no effect of cholecalciferol supplementation on cardiovascular events, kidney disease progression, and albuminuria. Long-term supplementation does not appear to be associated with kidney stone disease. Vitamin D supplementation decreases parathyroid hormone (PTH) levels and high levels of 25-hydroxyvitamin D may be required for maximal suppression.SummaryThere appear to be no effects of vitamin D supplementation on noncalcemic outcomes including progression of kidney disease, albuminuria, or cardiovascular disease. The primary reason to use vitamin D in kidney disease remains to lower PTH levels.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalCurrent opinion in nephrology and hypertension
Volume29
Issue number2
DOIs
StatePublished - Mar 1 2020

    Fingerprint

Keywords

  • Cardiovascular disease
  • Kidney disease
  • Kidney stones
  • Secondary hyperparathyroidism
  • Vitamin D

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Cite this